Gambro Pathogen Reduction Technologies, Inc. – Trademark Portfolio
Entity Type: 03
Gambro Pathogen Reduction Technologies, Inc. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include MIRASOL. The owner is based in Lakewood, CO.
10810 W. Collins Ave.
Lakewood, CO 80215
Showing of trademarks Trademarks
Trademark Classifications
Gambro Pathogen Reduction Technologies, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Gambro Pathogen Reduction Technologies, Inc. have?
Gambro Pathogen Reduction Technologies, Inc. has 7 U.S. trademarks filed with the USPTO. Of these, 2 registered, 4 abandoned, 1 cancelled.
What trademark classes does Gambro Pathogen Reduction Technologies, Inc. file in?
Gambro Pathogen Reduction Technologies, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Gambro Pathogen Reduction Technologies, Inc.'s most well-known trademarks?
Gambro Pathogen Reduction Technologies, Inc.'s registered trademark portfolio includes well-known marks such as MIRASOL. These are among 2 currently registered trademarks in the portfolio.
What is Gambro Pathogen Reduction Technologies, Inc.'s trademark registration success rate?
Gambro Pathogen Reduction Technologies, Inc. has a 29% trademark registration rate, with 2 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.